Scarica l'app Stockscreener
25.56
0.95%
0.24
Dopo l'orario di chiusura:
25.56
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CSTL Giù?
Forum
Previsione
Precedente Chiudi:
$25.32
Aprire:
$25.4
Volume 24 ore:
245.49K
Relative Volume:
0.61
Capitalizzazione di mercato:
$759.93M
Reddito:
$344.23M
Utile/perdita netta:
$-24.16M
Rapporto P/E:
-30.17
EPS:
-0.8471
Flusso di cassa netto:
$28.33M
1 W Prestazione:
-5.75%
1M Prestazione:
-22.90%
6M Prestazione:
+19.33%
1 anno Prestazione:
+36.25%
Intervallo 1D:
$25.20
$26.13
Intervallo di 1 settimana:
$24.89
$27.36
Portata 52W:
$14.59
$44.28
Castle Biosciences Inc Stock (CSTL) Company Profile
Nome
Castle Biosciences Inc
Settore
Industria
Telefono
866-788-9007
Indirizzo
1500 W. PARKWOOD AVE., FRIENDSWOOD, TX
Compare CSTL vs TMO, DHR, IDXX, A, WAT
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
25.56 | 759.93M | 344.23M | -24.16M | 28.33M | -0.8471 |
|
TMO
Thermo Fisher Scientific Inc
|
464.37 | 172.51B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
187.32 | 132.46B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
573.82 | 45.69B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
111.51 | 31.51B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
286.57 | 28.11B | 3.17B | 642.63M | 516.49M | 10.77 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-01-07 | Iniziato | Stephens | Overweight |
| 2021-04-30 | Iniziato | Lake Street | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2019-12-27 | Reiterato | Canaccord Genuity | Buy |
| 2019-08-19 | Iniziato | BTIG Research | Buy |
| 2019-08-19 | Iniziato | Canaccord Genuity | Buy |
| 2019-08-19 | Iniziato | Robert W. Baird | Outperform |
| 2019-08-19 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Castle Biosciences Inc Borsa (CSTL) Ultime notizie
Castle Biosciences (CSTL) Study Validates DecisionDx-Melanoma Te - GuruFocus
Castle Biosciences (CSTL) CEO sells 44,125 shares under 10b5-1 plan - Stock Titan
Prospective, Multi-center Study Published in Future - GlobeNewswire
New melanoma test flags patients who can skip lymph node biopsy - Stock Titan
Stokes Frank sells Castle Biosciences (CSTL) stock worth $192k - Investing.com Nigeria
Castle Biosciences Inc (CSTL) CFO Frank Stokes Sells 6,001 Shares - GuruFocus
Insider Selling: Castle Biosciences (NASDAQ:CSTL) CFO Sells 6,001 Shares of Stock - MarketBeat
Insider Selling: Castle Biosciences (NASDAQ:CSTL) Director Sells 7,403 Shares of Stock - MarketBeat
Castle Biosciences (CSTL) CFO sells 6,001 shares under 10b5-1 plan - Stock Titan
Castle Biosciences (CSTL) director exercises options and sells shares - Stock Titan
DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest - GlobeNewswire
DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk - Sahm
Aug Wrap: Whats next for Castle Biosciences Inc stockVolume Spike & Expert Verified Movement Alerts - baoquankhu1.vn
Death Cross: Will Castle Biosciences Inc benefit from current market trendsEarnings Growth Summary & Low Volatility Stock Suggestions - baoquankhu1.vn
How Castle Biosciences (CSTL) Story Is Shifting With New Revenue Targets And Fair Value - Yahoo Finance
Stokes Frank sells Castle Biosciences (CSTL) stock worth $192k By Investing.com - Investing.com India
Frank Stokes Sells 7,000 Shares of Castle Biosciences (NASDAQ:CSTL) Stock - MarketBeat
Castle Biosciences: Interview With Founder, CEO, And President Derek Maetzold About The Molecular Diagnostics Company - Pulse 2.0
Castle Biosciences Stock Hits Day Low of $27.22 Amid Price Pressure - Markets Mojo
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b-T2a Melanoma Patients Who May Safely Avoid SLNB - The Manila Times
Melanoma test may let some patients skip lymph node surgery - Stock Titan
Castle Biosciences (NASDAQ:CSTL) Lowered to Hold Rating by Zacks Research - MarketBeat
Castle Biosciences to Present Data at SSO 2026 on DecisionDx-Melanoma's i31-SLNB, Identifying T1b-T2a Melanoma Patients Who May Safely Avoid SLNB - Bitget
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas - Bitget
Morgan Stanley lists 7,000 CSTL RSU shares for sale (CSTL) - Stock Titan
CSTL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Canaccord reiterates Castle Biosciences stock rating on Q4 beat By Investing.com - Investing.com India
Canaccord reiterates Castle Biosciences stock rating on Q4 beat - Investing.com Nigeria
Aug Volume: What is the target price for Seer Inc stockEarnings Beat & Community Shared Stock Ideas - baoquankhu1.vn
Q4 2025 Castle Biosciences Inc Earnings Call Transcript - GuruFocus
Castle Biosciences, Inc. (NASDAQ:CSTL) Q4 2025 Earnings Call Transcript - Insider Monkey
Castle Biosciences (CSTL) Receives a Buy from Lake Street - The Globe and Mail
Castle Biosciences, Inc. (CSTL) Stock Analysis: Unveiling a Promising 50.96% Upside for Investors - DirectorsTalk Interviews
Castle Biosciences (NASDAQ:CSTL) Shares Gap DownWhat's Next? - MarketBeat
Pacira BioSciences Q4 Earnings and Revenues Miss Estimates, Stock Down - Finviz
Castle Biosciences (CSTL) Analyst Rating Update: Baird Raises Pr - GuruFocus
Robert W. Baird Forecasts Strong Price Appreciation for Castle Biosciences (NASDAQ:CSTL) Stock - MarketBeat
Expert Outlook: Castle Biosciences Through The Eyes Of 6 Analysts - Benzinga
Castle Biosciences, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:CSTL) 2026-02-27 - Seeking Alpha
Castle Biosciences, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Castle Biosciences Inc (CSTL) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges - GuruFocus
Transcript : Castle Biosciences, Inc., Q4 2025 Earnings Call, Feb 26, 2026 - marketscreener.com
Castle Biosciences Q4 2025 slides: test volumes surge 42%, enters AD market - Investing.com Nigeria
Volatility Watch: Will Castle Biosciences Inc stock go up in YEAR2025 Bull vs Bear & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Castle Biosciences (NASDAQ:CSTL) Releases Earnings Results - MarketBeat
Castle Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Castle Biosciences (CSTL) Expects Revenue Growth by 2026 - GuruFocus
Castle Biosciences (CSTL) Earnings Transcript - AOL.com
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Castle Biosciences Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Castle Biosciences Q4 2025 beats expectations, stock rises - Investing.com
Castle Biosciences Inc Azioni (CSTL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.34%
0.59%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):